Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
about
Crizotinib resistance: implications for therapeutic strategiesTackling ALK in non-small cell lung cancer: the role of novel inhibitorsOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerNovel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapiesOvercoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesExpert consensus on image-guided radiofrequency ablation of pulmonary tumors-2015 editionExpert consensus on image-guided radiofrequency ablation of pulmonary tumors-2015 editionManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerClinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsStereotactic body radiotherapy: current strategies and future developmentRe-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired ResistanceLeveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid TumorsSystemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.Stereotactic body radiation therapy for oligoprogression of metastatic disease from gastrointestinal cancers: A novel approach to extend chemotherapy efficacy.A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancerRadical irradiation of extracranial oligometastases.Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.Novel agents in development for advanced non-small cell lung cancer.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach.Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.EGFR: The Paradigm of an Oncogene-Driven Lung CancerExpert consensus on image-guided radiofrequency ablation of pulmonary tumors-2015 edition.PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsClinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.Distribution and prognosis of uncommon metastases from non-small cell lung cancerPROFILE 1014: lessons for the new era of lung cancer clinical research.Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?Pruning Cancer's Evolutionary Tree with Lesion-Directed Therapy.
P2860
Q26738381-0406D316-39FE-446D-83BA-9ADAA9B08DE2Q26740329-AA33BDA4-7E09-409E-85B0-8204C896D7FAQ26745427-98ECE861-6CE0-4358-A6D1-E003183C0D9FQ26775388-342A60D3-8475-4456-B13B-535D5366256EQ26795556-7864A1F6-758A-4E31-B705-6A88A9766754Q26797297-22AEAF16-1C7B-4C5D-88CC-15DA377D2656Q26799842-E92BB9F9-9CFE-48AC-BE91-5ED1A5C80C7AQ26799881-25BCF6ED-92EF-47BB-B57D-6E25B58375ABQ26865779-9BE82C13-E695-423A-8CC1-E274486482C7Q27852806-A873A1E2-C3F4-4B33-959F-78AF50E8BE9DQ27853360-49634FF6-FF33-4F19-8EBD-0C74498BE4BEQ28075291-C309AE73-5444-4B07-AC98-F400C061A0CEQ28076058-64279298-9EDC-4B7D-AB4F-CBC79FA369FDQ28083239-7CE5990C-630C-4206-B7A7-4E2EF2544ACEQ28553729-4D2F7987-11F6-47B9-B91F-7BC14D6061C5Q30239901-6D8FB8BA-B6ED-461F-B043-F76B9A1B589BQ30248748-F47506C5-90A8-4AFD-A398-2024A05209F6Q30850656-C6255417-80BC-42CC-B2D8-97332E2C7733Q33591738-00A66051-E70C-443A-BF9D-8BD019201924Q33599443-B5D2D916-A85D-4381-B04D-D10555500549Q33865475-46BD3AA6-9145-4CB4-984B-3B081F872418Q34019159-98B7F5AB-57F4-432B-9149-FCB115758087Q34124296-322121CE-4F7F-405E-AE64-37D8C1CA70DAQ34163370-09F9DA2F-BF0D-463A-A735-46A1E7DC0414Q34359274-34B7399A-7EC8-460A-AAF9-30ECE23705BAQ34388696-82D0B570-550D-483B-B327-07C83FA184D5Q34389263-721DBADA-4FE1-469C-BE10-A0E2741F13C0Q34497467-241F6527-5586-4A0E-B230-D06670D8553FQ35136424-153A4D4D-1D23-450C-965C-0D4C80FF6BBFQ35229098-8F396E30-24FE-4821-A085-36020A005779Q35549714-07F66F75-49F0-4A6E-A3F5-54EA9E3BAD58Q35619241-CA5D020C-34F8-4541-8E99-5F288871D042Q35681002-7DC2F950-3B05-46C1-B48C-669820C25663Q35858617-18E2E426-663B-4BCB-A867-54B6DF81DC59Q35909271-CC7500FC-81EB-4BB4-9878-C4E0C13AE32DQ35918612-6F458841-F14A-49B8-9B50-051FC2AE8D3BQ35934768-1BAEE4C1-7040-414C-9713-835D1D41B613Q36241808-4C5945D5-4342-4B71-B2F1-1B846AE8FF7AQ36322851-67F42EA0-759E-4607-BE1D-F5FD4A4B7032Q36560401-CDEB42F3-736F-41A2-90AD-944FB51C6E3B
P2860
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Local ablative therapy of olig ...... ed non-small-cell lung cancer.
@ast
Local ablative therapy of olig ...... ed non-small-cell lung cancer.
@en
type
label
Local ablative therapy of olig ...... ed non-small-cell lung cancer.
@ast
Local ablative therapy of olig ...... ed non-small-cell lung cancer.
@en
prefLabel
Local ablative therapy of olig ...... ed non-small-cell lung cancer.
@ast
Local ablative therapy of olig ...... ed non-small-cell lung cancer.
@en
P2093
P2860
P1476
Local ablative therapy of olig ...... ed non-small-cell lung cancer.
@en
P2093
Andrew J Weickhardt
Benjamin Scheier
Brian D Kavanagh
D Ross Camidge
Dara L Aisner
Gregory Gan
Joseph Malachy Burke
Laurie E Gaspar
Paul A Bunn
Robert C Doebele
P2860
P304
P356
10.1097/JTO.0B013E3182745948
P577
2012-12-01T00:00:00Z